<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865744</url>
  </required_header>
  <id_info>
    <org_study_id>Sema21</org_study_id>
    <nct_id>NCT04865744</nct_id>
  </id_info>
  <brief_title>The Effect of Semaglutide on Pituitary Function</brief_title>
  <official_title>The Effect of Semaglutide on Pituitary Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tartu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7&#xD;
      mg on growth hormone secretion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The randomized blinded placebo-controlled clinical trial is conducted on 10 healthy&#xD;
      volunteers.&#xD;
&#xD;
      Each study subject receives once 7 mg of oral semaglutide and once placebo. The order of&#xD;
      administration of study medication is decided on randomization. The placebo and oral&#xD;
      semaglutide are administered at least 4 weeks apart.&#xD;
&#xD;
      Blood samples are taken before and during 4 hours after the study medication administration&#xD;
      (at 60, 90, 120, 150, 180, and 240 minutes after study medication administration).&#xD;
&#xD;
      The primary endpoint is the peak value of growth hormone measured during the 4 hours after&#xD;
      study medication administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Blinded Randomised Single-group Crossover</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth hormone peak</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>Maximum concentration measured after study medication administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cortisol peak</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>Maximum concentration measured after study medication administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adrenocorticotropin (ACTH) peak</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>Maximum concentration measured after study medication administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone peak</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>Maximum concentration measured after study medication administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose nadir</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>Lowest glucose concentration measured after study medication administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide peak</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>Maximum concentration measured after study medication administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copeptin peak</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>Maximum concentration measured after study medication administration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Nausea</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>The intensity of nausea on a visual analog scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>The change in heart rate compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>60, 90, 120, 150, 180 and 240 minutes after study medication administration</time_frame>
    <description>The change in blood pressure compared to baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oral semaglutide 7 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The semaglutide 7 mg tablet taken orally with 120 ml of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo tablet taken orally with 120 ml of water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 7 MG Oral Tablet</intervention_name>
    <description>Semaglutide 7 mg oral tablet taken after an overnight fast with 120 ml of water.</description>
    <arm_group_label>Oral semaglutide 7 mg</arm_group_label>
    <other_name>Rybelsus 7 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet is taken after an overnight fast with 120 ml of water.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-50 years&#xD;
&#xD;
          -  The body weight &gt;65 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of chronic illness&#xD;
&#xD;
          -  the daily use of medications&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vallo Volke, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vallo Volke, MD,PhD</last_name>
    <phone>7374330</phone>
    <phone_ext>+372</phone_ext>
    <email>vallo.volke@ut.ee</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tartu</investigator_affiliation>
    <investigator_full_name>Vallo Volke</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

